{
    "clinical_study": {
        "@rank": "129679", 
        "brief_summary": {
            "textblock": "RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing\n      so they stop growing or die. Combining more than one drug may kill more tumor cells.\n\n      PURPOSE: Phase II trial to study the effectiveness of combining doxorubicin, paclitaxel, and\n      carboplatin in treating patients who have primary stage III, stage IV, or recurrent\n      endometrial cancer."
        }, 
        "brief_title": "Doxorubicin, Paclitaxel, and Carboplatin in Treating Patients With Primary Stage III, Stage IV, or Recurrent Endometrial Cancer", 
        "completion_date": {
            "#text": "January 2003", 
            "@type": "Actual"
        }, 
        "condition": "Endometrial Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Endometrial Neoplasms", 
                "Sarcoma, Endometrial Stromal"
            ]
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n        -  Determine the response rate and duration of response in patients with primary stage III\n           or IV or recurrent endometrial cancer treated with sequential doxorubicin, paclitaxel,\n           and carboplatin.\n\n      OUTLINE: Patients receive sequential chemotherapy comprised of doxorubicin IV once every 2\n      weeks for 3 courses, followed by paclitaxel IV over 1 hour once weekly for 9 courses, and\n      then carboplatin IV once every 3 weeks for 3 courses in the absence of disease progression\n      or unacceptable toxicity.\n\n      PROJECTED ACCRUAL: A total of 18-46 patients will be accrued for this study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS:\n\n          -  Histologically proven primary stage III or IV or recurrent endometrial cancer\n\n          -  Bidimensionally measurable disease by x-ray, CT scan, MRI scan, or physical exam\n\n               -  Sole site may be within a previously irradiated area if documented disease\n                  progression since prior radiotherapy\n\n        PATIENT CHARACTERISTICS:\n\n        Age:\n\n          -  Adult\n\n        Performance status:\n\n          -  Karnofsky 70-100%\n\n        Life expectancy:\n\n          -  At least 12 weeks\n\n        Hematopoietic:\n\n          -  Absolute neutrophil count greater than 1,000/mm^3\n\n          -  Platelet count at least 100,000/mm^3\n\n        Hepatic:\n\n          -  Bilirubin, SGOT, and alkaline phosphatase no greater than 1.5 times normal\n\n        Renal:\n\n          -  Creatinine no greater than 1.8 mg/dL\n\n        Cardiovascular:\n\n          -  Left ventricular ejection fraction at least 50%\n\n        Other:\n\n          -  No active uncontrolled infection\n\n          -  No greater than grade II neuropathy\n\n          -  No other active malignancy\n\n          -  Not pregnant\n\n          -  Negative pregnancy test\n\n          -  Fertile patients must use effective contraception\n\n        PRIOR CONCURRENT THERAPY:\n\n        Biologic therapy:\n\n          -  Not specified\n\n        Chemotherapy:\n\n          -  No prior doxorubicin\n\n          -  Greater than 6 months since prior paclitaxel, carboplatin, or other platinum\n             compounds\n\n        Endocrine therapy:\n\n          -  Not specified\n\n        Radiotherapy:\n\n          -  See Disease Characteristics\n\n          -  At least 4 weeks since prior radiotherapy and recovered\n\n        Surgery:\n\n          -  Not specified"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "October 4, 2000", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00006377", 
            "org_study_id": "00-073", 
            "secondary_id": [
                "CDR0000068251", 
                "NCI-G00-1860"
            ]
        }, 
        "intervention": [
            {
                "intervention_name": "carboplatin", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "doxorubicin hydrochloride", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "paclitaxel", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Doxorubicin", 
                "Carboplatin", 
                "Paclitaxel"
            ]
        }, 
        "keyword": [
            "stage III endometrial carcinoma", 
            "stage IV endometrial carcinoma", 
            "recurrent endometrial carcinoma"
        ], 
        "lastchanged_date": "June 17, 2013", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/MSKCC-00073"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "New York", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "10021"
                }, 
                "name": "Memorial Sloan-Kettering Cancer Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Phase II Study of Sequential Administration of Doxorubicin, Paclitaxel, and Carboplatin in Patients With Advanced and Recurrent Endometrial Cancer", 
        "overall_official": {
            "affiliation": "Memorial Sloan-Kettering Cancer Center", 
            "last_name": "Paul Sabbatini, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2003", 
            "@type": "Actual"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00006377"
        }, 
        "source": "Memorial Sloan-Kettering Cancer Center", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Memorial Sloan-Kettering Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2000", 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }, 
    "geocoordinates": {
        "Memorial Sloan-Kettering Cancer Center": "40.714 -74.006"
    }
}